TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30346481
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg orally twice daily for ≤3 years (minimum 1 year unless recurrence, second primary malignancy, significant toxicity, or consent withdrawal)
Study: 25765462
Drug: Mesalazine 2
Normalized name: mesalazine 2 GM per 59 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 2 g twice daily
Study: 24991045
Drug: Buttermilk drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buttermilk drink containing 1.5 lutein-rich egg yolks daily for 1 year
Study: 18384442
Drug: Budesonide (1000-mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1000-mug dose via dry powder inhaler)
Study: 18384442
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (1000-mug dose via dry powder inhaler)
Study: 9915317
Drug: Target effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target effect compartment concentration of propofol (5.4 microg/ml)
Study: 9915317
Drug: Target central
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target central compartment concentration of propofol (5.4 microg/ml)
Study: 7005134
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg, two days a week, for eight weeks
Study: 31266489
Drug: Glycopyrrolate 15.6
Normalized name: GLYCOPYRROLATE 15.6MCG CAP,INHL,60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 15.6 μg twice daily
Study: 29724638
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine 9.1 mg
Study: 17284138
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole 9.75 mg
Study: 25068233
Drug: Isotretinoin therapy
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin therapy (20-30 mg/day) for 6 months associated with dietary supplement (twice a day)
Study: 25068233
Drug: Isotretinoin therapy
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin therapy (20-30 mg/day) for 6 months
Study: 9213879
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride (100 mg twice a day for 10 days)
Study: 9213879
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-steroidal anti-inflammatory drugs for rheumatoid arthritis, paracetamol for OA and vertebrogen syndrome)
Study: 1927946
Drug: Soluble aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin, 100 mg/day
Study: 6350247
Drug: Carbohydrate feeding
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate feeding (glucose polymer solution)
Study: 25029557
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (Gatorade®)
Study: 23629739
Drug: Monitoring weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monitoring weekly after 1 month
Study: 19808309
Drug: HeartMate I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartMate I LVAD implantation at centers performing <=4 DT implants
Study: 19808309
Drug: HeartMate I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartMate I LVAD implantation at centers performing >9 DT implants
Study: 15155328
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg succinylcholine
Study: 15155328
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg succinylcholine
Study: 1994867
Drug: Stanozolol treatment
Normalized name: Stanozolol
DrugBank: Stanozolol (DB06718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanozolol treatment in primary Raynaud's phenomenon
Study: 1994867
Drug: Stanozolol treatment
Normalized name: Stanozolol
DrugBank: Stanozolol (DB06718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanozolol treatment in systemic sclerosis
Study: 6500169
Drug: Ibuprofen (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (7 mg/kg of body-weight)
Study: 6500169
Drug: Aspirin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (15 mg/kg of body-weight)
Study: 31508504
Drug: Alternative solution
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative solution of polyphyletic bradoriids
Study: 29886423
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and Nifedipine slow release 30 mg
Study: 1463157
Drug: 0.06 to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 to 0.08 mg intrathecal morphine
Study: 1463157
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without morphine
Study: 22721546
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to medication
Study: 12683740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UV photo and photoaging information
Study: 10222548
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg qPM
Study: 2064494
Drug: Nutritional-hygienic intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional-hygienic intervention plus antihypertensive medication (diuretic, beta-blocker, alpha 1-antagonist, calcium antagonist, or ACE inhibitor)
Study: 6242795
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin infusion (CIVII)
Study: 18631958
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg daily (background therapy)
Study: 15114097
Drug: Induction (T-cell-depleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction (T-cell-depleting and interleukin-2 receptor antibodies)
Study: 15114097
Drug: T-cell-depleting antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell-depleting antibody induction
Study: 15114097
Drug: Anti-interleukin-2 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-interleukin-2 receptor antibodies
Study: 8224951
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment (ALT)
Study: 8224951
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment (DLT)
Study: 27663118
Drug: Immediate TMS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate TMS treatment (n=7)
Study: 27663118
Drug: Delayed TMS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed TMS treatment (n=3)
Study: 25420793
Drug: Intradermal sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal sodium stibogluconate (SSG)
Study: 17432693
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (Ginaton) 0.5 mg/kg
Study: 17432693
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (St. Thomas' cardioplegic solution only)
Study: 17469410
Drug: Transendoscopic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendoscopic saline injection with or without epinephrine + coaptive bipolar electrocoagulation or heater probe
Study: 17469410
Drug: Antisecretory agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory agents at high doses
Study: 12190367
Drug: homocysteine-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: homocysteine-lowering therapy with folic acid (1 mg/d), vitamin B12 (400 micro g/d), and vitamin B6 (10 mg/d) (n = 272)
Study: 12190367
Drug: homocysteine-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6
Study: 10202868
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (200 mg three times daily)
Study: 10202868
Drug: IM progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM progesterone (50 mg daily)
Study: 7795309
Drug: N-acetylcystein (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcystein (NAC) administration as a bolus of 100 mg/kg followed by a continuous infusion of 20 mg/kg/h during cardiopulmonary bypass (CPB)
Study: 101223
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg, 50 mg, and 100 mg twice daily
Study: 101223
Drug: Atenolol twice
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol twice daily
Study: 101223
Drug: Atenolol (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (once or twice daily)
Study: 27599598
Drug: FSC 50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 50/250 μg via Rotacaps/Rotahaler
Study: 27599598
Drug: FSC 50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 50/250 μg via Diskus
Study: 27599598
Drug: FSC 50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 50/250 μg via Rotacaps/Rotahaler and Diskus
Study: 24147895
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg day(-1)) and zinc sulphate (220 mg day(-1))
Study: 24147895
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg day(-1))
Study: 24147895
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (220 mg day(-1))
Study: 22209625
Drug: Capsaicin (TRPV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (TRPV1 agonist)
Study: 22209625
Drug: Cinnamaldehyde (TRPA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamaldehyde (TRPA1 agonist)
Study: 14525630
Drug: Intrapulmonary percussive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapulmonary percussive ventilation (IPV) during nebulizer treatment
Study: 10770541
Drug: GM‐CSF (sargramostim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (sargramostim) 250 microg subcutaneous injections three times per week for 24 weeks
Study: 1900410
Drug: Intravenous etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous etidronate disodium (136 patients)
Study: 27112319
Drug: Fear of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fear of Recurrence Therapy (FORT) intervention
Study: 22777592
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli vaginal tablets (L. brevis CD2, L. salivarius subsp. salicinius, L. plantarum)
Study: 22777592
Drug: Vaginal pH
Normalized name: Azo Vaginal pH Test Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal pH tablet (active comparator)
Study: 22777592
Drug: Probiotic lactobacilli
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lactobacilli vaginal tablets
Study: 12183688
Drug: d‐amphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (30 mg oral dose)
Study: 9990363
Drug: Calcipotriol (Dovonex)
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (Dovonex) ointment (50 micrograms/g) twice daily for up to 3 months
Study: 3419842
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine (2 mg or 4 mg) and pentazocine (15 mg or 30 mg)
Study: 3419842
Drug: Morphine (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2, 4, 8 or 16 mg)
Study: 3419842
Drug: Pentazocine (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (15, 30 or 60 mg)
Study: 31639063
Drug: Low-dose haMPCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose haMPCs (1.0 × 10^7 cells)
Study: 31639063
Drug: Mid-dose haMPCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose haMPCs (2.0 × 10^7 cells)
Study: 31639063
Drug: High-dose haMPCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose haMPCs (5.0 × 10^7 cells)
Study: 31639063
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of haMPCs
Study: 30077556
Drug: Midazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.25 mg kg−1) prior to alfaxalone (0.5 mg kg−1)
Study: 30077556
Drug: Alfaxalone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (0.5 mg kg−1) followed by midazolam (0.25 mg kg−1)
Study: 30077556
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV prior to alfaxalone administration (Control group)
Study: 17324531
Drug: Temozolomide (Temodar)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (Temodar) chemotherapy
Study: 17324531
Drug: Chemical hypoxic
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical hypoxic cell sensitizers or carbon ion therapy
Study: 15998892
Drug: PSA cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL
Study: 9719123
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (as in arm B) in consecutive patients after December 1993
Study: 30977301
Drug: LCIG-HV formulation
Normalized name: Perox HV-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCIG-HV formulation
Study: 30977301
Drug: LCIG-LV formulation
Normalized name: LV-FAH
DrugBank: LV-FAH (DB17686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCIG-LV formulation
Study: 21494175
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine (2 doses, 6 to 9 months apart)
Study: 21494175
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine coadministered with DTaP and Hib vaccines (2 doses of HAV vaccine, 6 to 9 months apart)
Study: 21494175
Drug: DTaP and
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP and Hib vaccines followed by HAV vaccine (DTaP and Hib at 15 months, HAV 30 days later, second dose of HAV 7 to 10 months after DTaP+Hib)
Study: 19782785
Drug: Beta-blockers, aldosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers, aldosterone antagonists, CRT therapy
Study: 17370488
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of amiodarone
Study: 11174621
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation 5 mg/d (SG)
Study: 9753804
Drug: Intramuscular narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular narcotic injections (Group 2, n = 30)
Study: 8154809
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TS and FNAC
Study: 3144941
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (15 mg/kg)
Study: 3144941
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (1 g/m2 body surface area)
Study: 3144941
Drug: Intramuscular sodium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sodium aurothiomalate (up to 100 mg/week)
Study: 27521574
Drug: Atomoxetine (80-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (80-100 mg/day)
Study: 27885061
Drug: Alemtuzumab 12
Normalized name: alemtuzumab 12 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab 12 mg/day (5 days at baseline and 3 days at Month 12)
Study: 27885061
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a 44 µg three times/week
Study: 26422822
Drug: Transdiagnostic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive behavior therapy (TD‐CBT)
Study: 26422822
Drug: Disorder-specific cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder-specific cognitive behavior therapy (DS‐CBT)
Study: 21753868
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment consisting of daily pelvic floor muscle training with weekly supervision for 2 months.
Study: 21753868
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after treatment for 2 months.
Study: 25796337
Drug: Both rHA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both rHA and HSA formulations
Study: 8936516
Drug: terbutaline injection
Normalized name: terbutaline Injection
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: terbutaline injection
Study: 8936516
Drug: sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile water injection (control)
Study: 6808622
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (administered via metered dose aerosol at a lower dose than currently used)
Study: 29678969
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of the EHR to default to a dispense quantity of 10 tablets
Study: 27906598
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 with oral dexamethasone 8 mg q8 hours
Study: 27906598
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 with sustained release oral nifedipine 20 mg q8 hours
Study: 24587571
Drug: Zolpidem 3.5
Normalized name: zolpidem 3.5 mg sublingual tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 3.5 mg (ZST)
Study: 20307353
Drug: Intervention 1
Normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention 1 (60 g WG/d for 16 weeks)
Study: 20307353
Drug: Intervention 2
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention 2 (60 g WG/d for 8 weeks followed by 120 g WG/d for 8 weeks)
Study: 18559985
Drug: Tertatolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol (beta-adrenergic receptor antagonist)
Study: 18559985
Drug: Phentolamine (alpha-AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (alpha-AR antagonist)
Study: 7038977
Drug: Ancrod (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod (daily subcutaneous injections)
Study: 31480676
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (WG) 40 g/day
Study: 31480676
Drug: Hydrolysed Collagen
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolysed Collagen (CG) 38 g/day
Study: 26765515
Drug: Feedback group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback group (provided with activity and sleep data during each HD treatment)
Study: 22803426
Drug: Ligustrazine Injection
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine Injection (LI) 2 mg/kg given by intravenous dripping 30 min before autologous blood collection
Study: 22803426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Ligustrazine Injection)
Study: 18039195
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination inhalers containing F/S
Study: 18039195
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or parenteral corticosteroids (7-14 days) and other medications (retrospective group)
Study: 18039195
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or parenteral corticosteroids (7-14 days) and other medications (prospective group)
Study: 1417008
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 400 mg/m2
Study: 1417008
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 350 mg/m2
Study: 3857335
Drug: Mandibular repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular repositioning treatment
Study: 3857335
Drug: Flat plane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat plane occlusal splint treatment
Study: 29861388
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg for 16 weeks
Study: 19061675
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha plus ribavirin (peg‐IFNalpha/RBV) treatment for 48 weeks